← Back to Search

CTC Detection

Control for Human Papillomavirus

N/A
Waitlist Available
Led By Leslie Boyd, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.

Eligible Conditions
  • Human Papillomavirus
  • Cervical Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Group I: ControlExperimental Treatment1 Intervention
Participants without a history of cervical cancer or high grade pre-cancer of the cervix
Group II: Cervical CancerExperimental Treatment1 Intervention
Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood Assayed for CTCs
2020
N/A
~10

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,397 Previous Clinical Trials
861,838 Total Patients Enrolled
Leslie Boyd, MDPrincipal InvestigatorNYU Langone Health
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top